Source-based morphometry reveals structural brain pattern abnormalities in 22q11.2 deletion syndrome.

"CC was reported support by U54EB020403 from the Big Data to Knowledge (BD2K) Program; R01MH116147‐04; R01AG058854‐02; R01MH129742‐01. GB was supported by European Commision grant: QLGU‐CT‐2001‐01081; NWO‐Veni grant 2006 ‐916.76.048; Dutch Brain Foundation: 15F07(2).55. ASB was supported by the Dalglish Family Chair in 22q11.2 Deletion Syndrome, Canadian Institutes of Health Research (CIHR) (MOP‐313331 and MOP‐111238), and NIMH grant number U01MH119741‐01. TvA was supported by the NIH via grants NIMH. ED reports support from Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115300 (for EU‐AIMS) and No. 777394 (for AIMS‐2‐TRIALS). JLD was supported by a Wellcome Trust Clinical Research Training Fellowship (102003/Z/13/Z). MJ was supported by NIH grants K01MH112774 and R01MH129636 and a Next Generation Award from the Tommy Fuss Center for Neuropsychiatric Research. WRK was supported by NIH (R01 MH064824). DL reports support by Wellcome Trust Strategic Award “DEFINE”. DMM receives research support from NIH via grant 5U01MH119737‐04. DGM reports support by Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115300 (for EU‐AIMS) and No. 777394 (for AIMS‐2‐TRIALS). MJO was supported by the NIH via grants NIMH U01MH119738 and U01MH101724 and the MRC via grant MR/T033045/1, MR/N022572/1, and MR/L011166/1. JVR was supported by the NIH via grants R01MH129742 and R01MH116147. GMR was supported by Fondecyt grants 1171014 and 1211411, and ACT 192064 (ANID‐Chile). KA was supported by NIH R01MH107018 and U54HD079125. MvdB was supported by the NIH via grants NIMH U01MH119758 and U01MH101724 and the MRC via grant MR/T033045/1, MR/N022572/1 and MR/L011166/1. JV was supported by The SickKids Psychiatry Associates Chair in Developmental Psychopathology and NIMH U01MH119741‐01. PMT was supported by the NIH via grants R01MH129742 and R01MH116147. CEB was supported by U54EB020403 from the Big Data to Knowledge (BD2K) Program, NIMH R01MH085953, NIMH U01MH101719. FVR receives research support from CIHR, Brain Canada, Michael Smith Foundation for Health Research, Vancouver Coastal Health Research Institute, and Weston Brain Institute for investigator‐initiated research. Philanthropic support from Seedlings Foundation. In‐kind equipment supports for this investigator‐initiated trial from MagVenture. He has received honoraria for participation in an advisory board for Allergan."

"CC was reported support by U54EB020403 from the Big Data to Knowledge (BD2K) Program; R01MH116147‐04; R01AG058854‐02; R01MH129742‐01. GB was supported by European Commision grant: QLGU‐CT‐2001‐01081; NWO‐Veni grant 2006 ‐916.76.048; Dutch Brain Foundation: 15F07(2).55. ASB was supported by the Dalglish Family Chair in 22q11.2 Deletion Syndrome, Canadian Institutes of Health Research (CIHR) (MOP‐313331 and MOP‐111238), and NIMH grant number U01MH119741‐01. TvA was supported by the NIH via grants NIMH. ED reports support from Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115300 (for EU‐AIMS) and No. 777394 (for AIMS‐2‐TRIALS). JLD was supported by a Wellcome Trust Clinical Research Training Fellowship (102003/Z/13/Z). MJ was supported by NIH grants K01MH112774 and R01MH129636 and a Next Generation Award from the Tommy Fuss Center for Neuropsychiatric Research. WRK was supported by NIH (R01 MH064824). DL reports support by Wellcome Trust Strategic Award “DEFINE”. DMM receives research support from NIH via grant 5U01MH119737‐04. DGM reports support by Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115300 (for EU‐AIMS) and No. 777394 (for AIMS‐2‐TRIALS). MJO was supported by the NIH via grants NIMH U01MH119738 and U01MH101724 and the MRC via grant MR/T033045/1, MR/N022572/1, and MR/L011166/1. JVR was supported by the NIH via grants R01MH129742 and R01MH116147. GMR was supported by Fondecyt grants 1171014 and 1211411, and ACT 192064 (ANID‐Chile). KA was supported by NIH R01MH107018 and U54HD079125. MvdB was supported by the NIH via grants NIMH U01MH119758 and U01MH101724 and the MRC via grant MR/T033045/1, MR/N022572/1 and MR/L011166/1. JV was supported by The SickKids Psychiatry Associates Chair in Developmental Psychopathology and NIMH U01MH119741‐01. PMT was supported by the NIH via grants R01MH129742 and R01MH116147. CEB was supported by U54EB020403 from the Big Data to Knowledge (BD2K) Program, NIMH R01MH085953, NIMH U01MH101719. FVR receives research support from CIHR, Brain Canada, Michael Smith Foundation for Health Research, Vancouver Coastal Health Research Institute, and Weston Brain Institute for investigator‐initiated research. Philanthropic support from Seedlings Foundation. In‐kind equipment supports for this investigator‐initiated trial from MagVenture. He has received honoraria for participation in an advisory board for Allergan."